Fig. 1.

Brain uptake of currently marketed statins after treatment with BMP-9. Effect of BMP-9 treatment on Oatp-mediated uptake of [³H]atorvastatin (A), [³H]pravastatin (B), and [³H]rosuvastatin (C) was measured via a multiple-time uptake in situ brain perfusion study. Animals were treated with BMP-9 (1 μg/kg, i.p.; 6-hour treatment) in the presence and absence of LDN193189 (10 mg/kg, i.p.; 1-hour pretreatment) and perfused with equal concentrations of radiolabeled statins (0.013 μM total concentration) for 2.5, 5, 10, and 20 minutes. Linear phases of uptake for [³H]atorvastatin (D), [³H]pravastatin (E), and [³H]rosuvastatin (F) are also shown. Results are expressed as mean ± S.D. of six animals per time point. Asterisks represent data points that were significantly different from control animals (*p < 0.05; **p < 0.01).